BRPI0607851A2 - compostos e usos dos mesmos - Google Patents
compostos e usos dos mesmosInfo
- Publication number
- BRPI0607851A2 BRPI0607851A2 BRPI0607851-6A BRPI0607851A BRPI0607851A2 BR PI0607851 A2 BRPI0607851 A2 BR PI0607851A2 BR PI0607851 A BRPI0607851 A BR PI0607851A BR PI0607851 A2 BRPI0607851 A2 BR PI0607851A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- patient
- group
- antidepressants
- vivo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/64—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D267/20—[b, f]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/30—Ortho- or ortho- and peri-condensed systems containing three rings containing seven-membered rings
- C07C2603/32—Dibenzocycloheptenes; Hydrogenated dibenzocycloheptenes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
COMPOSTOS E USOS DOS MESMOS. A presente invenção refere-se a antidepressivos de carga modificada e compostos conjugados a um grupo carregado ou a um grupo volumoso de maneira que resista à clivagem in vivo. A invenção fornece um método para tratar um paciente tendo uma doença inflamatória administrando ao paciente um composto da invenção.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65262405P | 2005-02-14 | 2005-02-14 | |
PCT/US2006/005006 WO2006088786A2 (en) | 2005-02-14 | 2006-02-13 | Compounds and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0607851A2 true BRPI0607851A2 (pt) | 2009-06-13 |
Family
ID=36916957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0607851-6A BRPI0607851A2 (pt) | 2005-02-14 | 2006-02-13 | compostos e usos dos mesmos |
Country Status (13)
Country | Link |
---|---|
US (1) | US20060281722A1 (pt) |
EP (1) | EP1850855A2 (pt) |
JP (1) | JP2008530129A (pt) |
KR (1) | KR20070103499A (pt) |
CN (1) | CN101160280A (pt) |
AU (1) | AU2006214517A1 (pt) |
BR (1) | BRPI0607851A2 (pt) |
CA (1) | CA2597306A1 (pt) |
IL (1) | IL185223A0 (pt) |
MX (1) | MX2007009797A (pt) |
NO (1) | NO20074252L (pt) |
TW (1) | TW200640467A (pt) |
WO (1) | WO2006088786A2 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2704836C (en) * | 2007-11-28 | 2015-12-29 | Nektar Therapeutics | Oligomer-tricyclic conjugates |
MX2010011101A (es) | 2008-04-11 | 2010-11-01 | Nektar Therapeutics | Conjugados de oligomero-propanamina sustituida con ariloxi. |
WO2011091050A1 (en) * | 2010-01-19 | 2011-07-28 | Nektar Therapeutics | Oligomer-tricyclic conjugates |
US20130102572A1 (en) * | 2011-04-12 | 2013-04-25 | Dow Pharmaceutical Sciences | Methods of treating skin conditions exhibiting telangiectasia |
EP3651751A4 (en) | 2017-07-13 | 2021-03-31 | Tonix Pharmaceuticals Holding Corp. | CYCLOBENZAPRINE AND AMITRYPTILENE ANALOGUES |
BR112022007503A2 (pt) | 2019-10-21 | 2022-07-12 | Alairion Inc | Derivados de ácido 3-(4-(11h-dibenzo[b,e][1,4]azepin-6-il)piperazin-1-il)- e 3-(4-(11h-dibenzo[b,f][1,4]oxazepin/tiazepin/diazepin-11-il)piperazin-1-il)-propanoico como moduladores de receptor de h1 e 5-ht2a para o tratamento de distúrbios do sono |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03184963A (ja) * | 1989-12-13 | 1991-08-12 | Hokuriku Seiyaku Co Ltd | ジベンズオキサゼピン誘導体 |
JPH04211071A (ja) * | 1990-03-05 | 1992-08-03 | Hokuriku Seiyaku Co Ltd | 多環式化合物 |
-
2006
- 2006-02-13 TW TW095104724A patent/TW200640467A/zh unknown
- 2006-02-13 WO PCT/US2006/005006 patent/WO2006088786A2/en active Application Filing
- 2006-02-13 BR BRPI0607851-6A patent/BRPI0607851A2/pt not_active Application Discontinuation
- 2006-02-13 EP EP06734920A patent/EP1850855A2/en not_active Withdrawn
- 2006-02-13 CN CNA2006800120863A patent/CN101160280A/zh active Pending
- 2006-02-13 AU AU2006214517A patent/AU2006214517A1/en not_active Abandoned
- 2006-02-13 US US11/352,846 patent/US20060281722A1/en not_active Abandoned
- 2006-02-13 CA CA002597306A patent/CA2597306A1/en not_active Abandoned
- 2006-02-13 JP JP2007555312A patent/JP2008530129A/ja active Pending
- 2006-02-13 MX MX2007009797A patent/MX2007009797A/es not_active Application Discontinuation
- 2006-02-13 KR KR1020077021012A patent/KR20070103499A/ko not_active Application Discontinuation
-
2007
- 2007-08-13 IL IL185223A patent/IL185223A0/en unknown
- 2007-08-21 NO NO20074252A patent/NO20074252L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IL185223A0 (en) | 2008-06-05 |
MX2007009797A (es) | 2007-11-06 |
CN101160280A (zh) | 2008-04-09 |
JP2008530129A (ja) | 2008-08-07 |
AU2006214517A1 (en) | 2006-08-24 |
WO2006088786A2 (en) | 2006-08-24 |
NO20074252L (no) | 2007-11-12 |
WO2006088786A3 (en) | 2007-04-19 |
KR20070103499A (ko) | 2007-10-23 |
EP1850855A2 (en) | 2007-11-07 |
US20060281722A1 (en) | 2006-12-14 |
CA2597306A1 (en) | 2006-08-24 |
TW200640467A (en) | 2006-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0609393B8 (pt) | usos de um composto 11-desóxi-prostaglandina | |
BR122019016628B8 (pt) | uso de uma composição compreendendo um derivado de hidróxi de atorvastatina ou sal farmaceuticamente aceitável do mesmo e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato para a fabricação de um medicamento para o tratamento de uma doença cardiovascular | |
BRPI0512213A (pt) | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto | |
BRPI0512220A (pt) | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto | |
BRPI0717697A2 (pt) | composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos | |
BRPI0410503B8 (pt) | composição tópica e uso da composição | |
BRPI0606902A2 (pt) | composto; método para o tratamento de uma doença ou distúrbio associado a atividade excessiva de bace em um paciente que dele necessite; método para modular a atividade de bace; composição farmacêutica | |
BRPI0713447A2 (pt) | composição forma de dosagem oral sólida, e, método para o tratamento de dor | |
BRPI0607851A2 (pt) | compostos e usos dos mesmos | |
BRPI0717219A2 (pt) | "composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica." | |
BRPI0513812B8 (pt) | método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical | |
BRPI0622054B8 (pt) | composto e composição farmacêutica | |
BRPI0413326A (pt) | métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel | |
BRPI0516830A (pt) | composições de droga de liberação sustentada convenientemente implantáveis | |
CR8411A (es) | Metodo para el tratamiento de la enfermedad asociada con adamts-5 | |
BRPI0616962B8 (pt) | uso de lactobacillus para o tratamento de doenças autoimunes | |
BR0312933A (pt) | Composição farmacêutica, unidade de dosagem farmacêutica, método para tratar uma ou mais doenças associadas com uma condição vascular, e, combinação terapêutica | |
EA200870254A1 (ru) | Способ лечения воспалительных заболеваний | |
BRPI0507657A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo | |
BRPI0511569A (pt) | composições e métodos para o tratamento de distúrbio disfórico pré-menstrual | |
ATE470151T1 (de) | Diagnose, behandlung und prävention von gefässerkrankungen mittels il-1alpha- autoantikörpern | |
DE602006015963D1 (de) | Immunstimulatorisches verfahren | |
ATE513562T1 (de) | Nicht-spezifische immunstimulierende mittel | |
EP2047850A3 (en) | Methods for treating diseases through inhibition of the function of molecular chaperones such as protein disulfide isomerases , pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents | |
CY1116938T1 (el) | Αναπληρωτικη θεραπεια της ασθενειας huntington και αλλων ασθενειων πολυγλουταμiνης |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |